Abstract

Aim: Despite the effectiveness of antipsychotic drugs over patients with schizophrenia and the drug resistance among these patients, the need for new drug mixtures is proposed to improve their treatment. This study is aimed to determine and compare the effect of mixed treatment using clozapine and risperidone with clozapine and ECT over patients with clozapine treatment-resistant schizophrenia referring to the comprehensive psychiatric center in Taft, Yazd, Iran.

Material and Method: In this clinical trial study, thirty patients with clozapine treatment-resistant schizophrenia were randomly assigned to receive co-administration of either clozapine and risperidone (n = 15) or clozapine and ECT (n = 15). Before the intervention, both groups completed the Positive and Negative Syndrome Scale (PANSS) questionnaire. Both groups received the intervention for six sessions, 3times per week. All of the participants completed the PANSS questionnaire again after the intervention. The data obtained were analyzed using SPSS as statistical tests, chi-square, and pair T.

Results: Having compared the index differences of the PANSS questionnaire before and after the treatment over patients treated with both mixtures, it was indicated that negative symptoms were decreased more notably in the clozapine and ECT group (P < 0.05). The decrease in the positive symptom indices, anxiety, and depression was significantly lower in the clozapine and risperidone group (P < 0.05), the decrease in the scores of the PANSS questionnaire was significantly more remarkable in the clozapine and ECT group (P < 0.05).

Conclusion: The results of this study indicated the effect of both mixed therapies, clozapine and risperidone, and clozapine and ECT in improving the positive and negative symptoms of schizophrenia. With regards to the more significant decrease in PANSS total score in the clozapine and ECT group, more studies are to be done on this treatment.

Keywords: Clozapine; Risperidone; ECT; Schizophrenia; Resistance to Clozapine

References

1. Wykes T HV., et al. “A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes”. Journal Psychiatry5 (2011): 472-485.
2. Brennand KJ SA., et al. “Modelling schizophrenia using human induced pluripotent stem cells”. Nature 7346 (2011): 221.
3. Lally J MJ. “Antipsychotic medication in schizophrenia: a review”. British Medical Bulletin1 (2015): 169-179.
4. Ho BC AN., et al. “Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia”. Archives of General Psychiatry2 (2011): 128-137.
5. Miller BJ BP., et al. “Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects”. Biological Psychiatry7 (2011): 663-671.
6. Catts SV OTB. “The treatment of schizophrenia: Can we raise the standard of care?” Australian and New Zealand Journal of Psychiatry12 (2016): 1128-1138.
7. Howes OD MR., et al. “Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology”. American Journal of Psychiatry 3 (2016): 216-229.
8. Sadocks K. Synopsis of psychiatry: Willams and Wilkins (2003).
9. Harrison G HK., et al. “Recovery from psychotic illness: a 15- and 25-year international follow-up study”. British Journal Psychiatry 178 (2001): 506-517.
10. Hamer S HP. “Adverse effects of antipsychotics as outcome measures”. British Journal Psychiatry 50 (2007): 64-70.
11. Chouinard G VJ., et al. “Risperidone and Clozapine in treatment of drug resistant schizophrenia and neuroleptic induced supersensitivity psychosis”. Progress in neurospsychopharmacology-psychiatry7 (1997): 1129-1141.
12. William G., et al. “Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia”. New England Journal of Medicine5 (2006): 472-482.
13. Kim SH., et al. “The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series”. Journal of Psychopharmacology7 (2010): 981-986.
14. Sim F SI., et al. “Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review”. Journal of Psychopharmacology2 (2015): 212-223.
15. Kho KH BB. “ECT for the treatment of clozapine nonresponders suffering from schinzophrenia”. European Archives of Psychiatry and Clinical Neuroscience 6 (2004): 327-329.
16. Petrides G MC., et al. “Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study”. American Journal Psychiatry1 (2015): 52-58.
17. Sandeep Grover NH and Natasha Kate. “Combined use of clozapine and ECT: a review”. Acta Neuropsychiatric3 (2015): 131-142.
18. Kay SR., et al. “The positive and Negative Syndrome Scale for schizophrenia”. Schizophrenia Bulletin 13 (1986): 261-276.
19. A A. “Metacognitive beliefs with positive and negative symptoms in schizophrenic patients”. Daneshvar Journal of Behavior25 (2008): 1-10.
20. Ghomri Givi H PM and Heshmati R. “Investigating the Factor Structure of the Positive and Negative Symptom Scale in Schizophrenic Spectrum Disorders”. Journal of Clinical Psychology2 (2011): 1-10.
21. Samadi R SS., et al. “Efficacy of risperidone augmentation with ondansetron in the treatment of negative and depressive symptoms in schizophrenia: A randomized clinical trial”. Iranian Journal of Medical Sciences1 (2017): 14.
22. Gupta D RM and Kurhe Y. “Ondansetron. a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system”. European Journal of Pharmacology 744 (2014): 59-66.
23. Lindenmayer JP BC., et al. “Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale”. Psychopathology 41 (2008): 264-270.
24. Pittenger C BM. “Pharmacological treatment of obsessive-compulsive disorder”. Psychiatric Clinics of North America 37 (2014): 375-391.
25. Kelly DL SK., et al. “Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients with Persistent Symptoms”. Journal of Clinical Psychopharmacology4 (2015): 374.
26. Liaury K MT., et al. “Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: a possible hyperbilirubinemia-induced animal model of schizophrenia”. Progress in Neuro-Psychopharmacology and Biological Psychiatry 50 (2014): 184-190.
27. Muscatello MR PG., et al. “Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study”. Journal of Clinical Psychopharmacology1 (2014).
28. Petrides G MC., et al. “Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study”. American Journal of Psychiatry1 (2014): 52-58.
29. Gul IG EG., et al. “Evaluation of th efficacy of the continuation electroconvulsive therapy in treatment-resistant schizophrenia”. Archives of Clinical Psychiatry (São Paulo) 4 (2014): 90-94.
30. Garg R CB and Arun P. “Short-term efficacy of electroconvulsive therapy in treatment-resistant schizophrenia”. German Journal of Psychiatry 15 (2012): 44-49.
31. Tiihonen J HJ., et al. “A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia”. Journal of Psychiatry6 (2015): 603-609.
32. Fett AK VW., et al. “The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis”. Neuroscience and Biobehavioral Reviews3 (2011): 573-588.

Citation

Citation: Bidaki Reza., et al. “Comparing the Effects of Mixed Treatment by Clozapine and Risperidone with Clozapine and ECT Over Patients with Clozapine Treatment-resistant Schizophrenia”. Acta Scientific Neurology 4.11 (2021): 03-09.

Copyright

Copyright: © 2021 Bidaki Reza., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.